ReviewFrontiers in immunology2026
Inflammation-driven immune reprogramming in sepsis: from cytokine storm to immunoparalysis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis remains a leading cause of preventable death, partly because its rapidly evolving and heterogeneous biology has often been treated as a uniform inflammatory syndrome in therapeutic development and clinical trials. This narrative review synthesizes recent advances in human immune profiling to reframe sepsis as an inflammation-driven immune reprogramming disorder characterized by time-resolved trajectories and biologically defined subtypes, in which hyperinflammation and low-response programs can arise in parallel and shift across compartments. We summarize core mechanisms linking early innate sensing, endothelial injury, coagulation-inflammation coupling, and cytokine network "instruction" to later immune paralysis, lymphocyte loss, functional exhaustion, and the chronic critical illness phenotype. We then translate these concepts into a practical interpretive framework for dynamic immune monitoring, emphasizing trends and composite signals over single biomarkers, and highlighting how misalignment of patient state, therapeutic direction, and timing helps explain past trial failures. Finally, we outline implications for next-generation interventions and study designs, arguing for bidirectional, time-stamped immunomodulation guided by repeated phenotyping, enriched enrollment, and endpoints that capture secondary infections, organ recovery trajectories, and longer-term functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.